S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
NASDAQ:NBSE

NeuBase Therapeutics Stock Forecast, Price & News

$3.97
+0.01 (+0.25 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.92
$4.10
50-Day Range
$3.27
$4.05
52-Week Range
$3.26
$12.89
Volume278,723 shs
Average Volume286,634 shs
Market Capitalization$129.89 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.01
30 days | 90 days | 365 days | Advanced Chart
Receive NBSE News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuBase Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


NeuBase Therapeutics logo

About NeuBase Therapeutics

NeuBase Therapeutics, Inc. is a biotechnology company. It engages in the development of drugs for patients with genetic neurological disorder. The firms pipelines include Huntington's Disease, NT0100 Program - PATrOL Enabled gamma-PNA for Huntington's Disease, and NT0200 Program- PATrOL Enabled gamma-PNA for Myotonic Dystophy. The company was founded by Dietrich A. Stephan on August 28, 2018 and is headquartered in Pittsburgh, PA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.80 out of 5 stars

Medical Sector

788th out of 1,352 stocks

Pharmaceutical Preparations Industry

387th out of 665 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











NeuBase Therapeutics (NASDAQ:NBSE) Frequently Asked Questions

Is NeuBase Therapeutics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeuBase Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NeuBase Therapeutics stock.
View analyst ratings for NeuBase Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than NeuBase Therapeutics?

Wall Street analysts have given NeuBase Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but NeuBase Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting NeuBase Therapeutics?

NeuBase Therapeutics saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 535,900 shares, a decline of 27.3% from the August 15th total of 737,100 shares. Based on an average daily volume of 209,800 shares, the days-to-cover ratio is currently 2.6 days.
View NeuBase Therapeutics' Short Interest
.

When is NeuBase Therapeutics' next earnings date?

NeuBase Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, December 22nd 2021.
View our earnings forecast for NeuBase Therapeutics
.

How were NeuBase Therapeutics' earnings last quarter?

NeuBase Therapeutics, Inc. (NASDAQ:NBSE) announced its earnings results on Thursday, February, 11th. The company reported ($0.18) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.23) by $0.05.
View NeuBase Therapeutics' earnings history
.

How has NeuBase Therapeutics' stock been impacted by Coronavirus?

NeuBase Therapeutics' stock was trading at $7.02 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NBSE shares have decreased by 43.4% and is now trading at $3.97.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for NBSE?

3 equities research analysts have issued twelve-month price objectives for NeuBase Therapeutics' shares. Their forecasts range from $15.00 to $17.00. On average, they anticipate NeuBase Therapeutics' stock price to reach $16.33 in the next year. This suggests a possible upside of 311.4% from the stock's current price.
View analysts' price targets for NeuBase Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are NeuBase Therapeutics' key executives?

NeuBase Therapeutics' management team includes the following people:
  • Dietrich A. Stephan, Chairman, President & Chief Executive Officer
  • William R. Mann, Chief Operating Officer
  • Samuel I. Backenroth, Chief Financial Officer, Secretary & Treasurer
  • Curt W. Bradshaw, Chief Scientific Officer
  • Sandra Rojas-Caro, Chief Medical Officer

What other stocks do shareholders of NeuBase Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeuBase Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD), Flexion Therapeutics (FLXN), Pfizer (PFE), VBI Vaccines (VBIV), AbbVie (ABBV) and Aravive (ARAV).

What is NeuBase Therapeutics' stock symbol?

NeuBase Therapeutics trades on the NASDAQ under the ticker symbol "NBSE."

Who are NeuBase Therapeutics' major shareholders?

NeuBase Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Greenlight Capital Inc. (8.34%), Vanguard Group Inc. (3.97%), Point72 Asset Management L.P. (3.82%), Renaissance Technologies LLC (1.30%), GSA Capital Partners LLP (1.06%) and Geode Capital Management LLC (0.71%). Company insiders that own NeuBase Therapeutics stock include Dietrich A Stephan, Eric I Richman and Samuel Backenroth.
View institutional ownership trends for NeuBase Therapeutics
.

Which institutional investors are selling NeuBase Therapeutics stock?

NBSE stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Northern Trust Corp, Geode Capital Management LLC, Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., and Tocqueville Asset Management L.P..
View insider buying and selling activity for NeuBase Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying NeuBase Therapeutics stock?

NBSE stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Greenlight Capital Inc., Vanguard Group Inc., GSA Capital Partners LLP, Renaissance Technologies LLC, Marshall Wace LLP, Marshall Wace LLP, and Millennium Management LLC. Company insiders that have bought NeuBase Therapeutics stock in the last two years include Dietrich A Stephan, Eric I Richman, and Samuel Backenroth.
View insider buying and selling activity for NeuBase Therapeutics
or or view top insider-buying stocks.

How do I buy shares of NeuBase Therapeutics?

Shares of NBSE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NeuBase Therapeutics' stock price today?

One share of NBSE stock can currently be purchased for approximately $3.97.

How much money does NeuBase Therapeutics make?

NeuBase Therapeutics has a market capitalization of $129.89 million. The company earns $-17,390,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis.

How many employees does NeuBase Therapeutics have?

NeuBase Therapeutics employs 15 workers across the globe.

What is NeuBase Therapeutics' official website?

The official website for NeuBase Therapeutics is www.neubasetherapeutics.com.

Where are NeuBase Therapeutics' headquarters?

NeuBase Therapeutics is headquartered at 700 TECHNOLOGY DRIVE, PITTSBURGH PA, 15219.

How can I contact NeuBase Therapeutics?

NeuBase Therapeutics' mailing address is 700 TECHNOLOGY DRIVE, PITTSBURGH PA, 15219. The company can be reached via phone at (164) 645-1790 or via email at [email protected].


This page was last updated on 9/26/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.